Treatment of chronic hepatitis B: Virological and pharmacological aspects (notice n° 234376)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02730cam a2200205 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112063600.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Foucault, Tristan |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Treatment of chronic hepatitis B: Virological and pharmacological aspects |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 41 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Tenofovir is a nucleotide analog inhibitor used in monotherapy as the first-line treatment for chronic hepatitis B virus (HBV) infection. This drug requires a two-step phosphorylation using cellular kinases. The active triphosphate form inhibits viral DNA polymerase. Tenofovir has a very low oral bioavailability following oral administration. As such, its oral administration requires the use of prodrugs: either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF). TAF has demonstrated a lower kidney and bone toxicity than TDF. TAF and TDF treatments enable prevention of chronic hepatitis B complications—cirrhosis and hepatocellular carcinoma. Prevention of these complications requires a virological response to the treatment, defined as undetectable HBV DNA. TDF and TAF have virological response rates ranging from 64 to 94% after one year of treatment. This rate depends on the HBV viral load at diagnosis, HBe antigen status, mutations in the HBV polymerase gene (Pol/RT), and patient compliance to the treatment. Tenofovir has a high genetic barrier and resistance mutations to this drug have not yet been described. However, mutations rt181T/V and/or rtN236T have been associated with reduced susceptibility to TDF/TAF in vitro and delayed response in vivo. The recently described mutations CYEI and rtA194T have been associated with reduced susceptibility to TDF/TAF in vitro without any change in viral response in vivo. Patient compliance can be improved using cognitive behavioral therapy, supporter interventions, and a text messaging service. Finally, some genetic polymorphisms in MRP2 (multidrug resistance-associated protein 2) and MRP4 (multidrug resistance-associated protein 4) efflux transporters could be associated with TDF toxicity and virological response to TDF or TAF. In terms of a functional HBV cure, TDF and TAF are likely to be still used, alongside new antivirals. For this reason, it is important to further characterize the pharmacological and virological factors associated with a partial virological response to tenofovir. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Handala, Lynda |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Paintaud, Gilles |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gaudy-Graffin, Catherine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Marlet, Julien |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Virologie | 26 | 3 | 2022-05-01 | p. 228-239 | 1267-8694 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-virologie-2022-3-page-228?lang=en">https://shs.cairn.info/journal-virologie-2022-3-page-228?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux